The unpopular take is that restraint, not speed, may be the smarter strategy here.

Insurance companies are scrambling to add obesity medications like semaglutide and tirzepatide to their drug formularies. CVS just restored coverage of Zepbound. Employers are fielding daily calls about adding these treatments. The narrative writes itself: innovative drugs, expanding access, progress.

But here's what's missing from that story: the actual math.

We don't yet know the long-term cost of covering GLP-1 drugs at scale. Yes, the clinical evidence for weight loss is real. Yes, some studies suggest downstream savings from reduced heart disease and diabetes. But those studies look at controlled populations over defined periods. Real insurance markets are messier. Patients drop treatment. Side effects vary. Follow-up care costs more than anyone initially budgets for.

Rushing coverage expansion before understanding true actuarial impact is how insurance premiums spike. And when premiums spike, the people who benefit most from these drugs (lower-income patients with obesity) are often the least able to afford coverage in the first place.

I'm not saying these medications shouldn't be covered. I'm saying that "as fast as possible" isn't the same as "as smart as possible."

Consider the timeline. These drugs have been on the market for diabetes management for over a decade. But their adoption for weight loss is genuinely new. We're talking about expanding from a niche population (people with type 2 diabetes) to potentially millions of new users (anyone with obesity). That's a different actuarial problem entirely.

Insurance companies have skin in the game, sure. But they also have a responsibility to the broader pool of insured people. Fast expansion without rigorous cost modeling isn't heroic. It's reckless. It shifts risk from drugmakers and prescribers onto everyone else's premiums.

Here's the pragmatic middle ground nobody wants to discuss: selective coverage expansion with built-in review points.

Insurers could offer these medications to specific populations first. High-risk patients with obesity plus comorbidities. Patients who've failed other treatments. People enrolled in structured weight-loss programs that include monitoring. This isn't gate-keeping. It's risk management with a purpose.

Then, collect real data for 18 to 24 months. Track adherence rates. Monitor for complications requiring additional care. Measure actual workplace productivity changes, not theoretical ones. Calculate the true cost per pound lost, per patient retained, per comorbidity improved.

Only then, with actual numbers instead of projections, expand coverage more broadly.

This approach sounds slower. It is. But it also prevents the scenario where insurance companies overcommit to a novel drug class, premiums explode, coverage gets yanked, and patients get whiplash.

We've seen this movie before. Remember when new cancer immunotherapies got rapid coverage expansion? Many insurers later restricted access as costs soared beyond projections. The drugs didn't change. Reality did.

The rush to cover GLP-1 drugs reflects something positive: enthusiasm for innovation and treatment options. But insurance isn't about enthusiasm. It's about sustainability. A plan that collapses under cost pressure doesn't help anyone.

I'm genuinely sympathetic to patients who could benefit from these medications and currently can't access them. That's a real problem. But the solution isn't to solve it in 90 days and regret it in 18 months.

Restraint here isn't cruelty. It's the difference between access that lasts and access that disappears when the financial reality catches up.

Sometimes slower actually means smarter.